131 -5 (55) 2023 — Tursunova D.E.,Mavlonov N.X. — RISK FACTORS AND MAIN ASPECTS OF LIPID METABOLISM DISTURBANCES

RISK FACTORS AND MAIN ASPECTS OF LIPID METABOLISM DISTURBANCES

Tursunova D.E., Bukhara State Medical Institute named after Abu Ali ibn Sina

Mavlonov N.X. Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Dyslipidemia is a disease characterized by a violation of the ratio of atherogenic and non-atherogenic lipoproteins, which tends to develop in modern society. In modern medicine, it has been proven that dyslipidemias include a wide range of disorders, and they play a leading role in the development of cardiovascular and neurological diseases with severe complications. This factor alone or in combination with other factors creates the risk of atherosclerosis. In recent years, much attention has been paid to the detection and treatment of elevated total cholesterol (TC) and LDL cholesterol. However, it has been proven that other forms of dyslipidemia can also cause the development of diseases.

Key words: hyperlipidemia, hypolipidemia, dyslipidemia, pathogenesis, complications.

First page

746

Last page

751

For citation: Tursunova D.E.,Mavlonov N.X. – RISK FACTORS AND MAIN ASPECTS OF LIPID METABOLISM DISTURBANCES //New Day in Medicine 2023 5 (55): 746-751 https://newdaymedicine.com/index.php/2023/06/19/l-205/

LIST OF REFERENCES:

  1. Abnormalities of glucose metabolism in patients with early renal failure [Text] / L.A. Sechi [et al.] Diabetes. 2002. 51(4):1226-1232.
  2. All-Cause Mortality up to and After Coronary Heart Disease and Stroke Events in European Middle-Aged Men [Text] / B. Majed [et al.] Stroke. 2015 46(5):1371-1373.
  3. Attman, P.O. Dyslipidemia of kidney disease [Text] / P.O. Attman, O. Samuelsson Curr Opin Lipidol. 2009 20:293-299.
  4. Baigent, C. Premature cardiovascular disease in chronic renal failure [Text] /C. Baigent, K. Burbur, D. Wheeler  Lancet. 2000 356:147-152.
  5. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia [Text] / R. Fogari [et al.]  J Cardiovasc Pharmacol. 1999 33:534-539.
  6. Brinton E.A. Effects of ethanol intake on lipoproteins and atherosclerosis [Text] / E.A. Brinton  Curr Opin Lipidol. 2010 21:346-351.
  7. Cappola, A. Hypothyroidism and atherosclerosis [Text] / A. Cappola, P. Lanenson J Clin Endocrinol Metab. – 2003 88:2438-2440.
  8. Carbohydrate intake is associated with diet quality and risk factors for cardiovascular diseases in US adults: NHANES III [Text] / E.J. Yang [et al.]  J Am Coll Nutr. – 2003 22:71-79.
  9. Chowdhury, I. Alcohol and Dyslipidemia [Text] / I. Chowdhury Alcohol, Nutrition, and Health Consequences.  2013 329-339. doi: 10.1007/978-1-62703-047-2_26
  10. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM [Text] / R. Malmstrom [et al.]  Diabetologia. 1997 40:454-462. doi: 10.1007/s001250050700
  11. Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation [Text] / K. Taira [et al.]  Eur. J. Clin. Invest. – 1999 29:301-308. doi: 10.1046/j.1365-2362.1999.00454.x.
  12. Drover V.A.B. Reguation of the human holesterol 7ά-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mise [Text] / V.A.B. Drover, L.B. Agellon  Endocrinol. – 2004 145:547-581.
  13. Effects of antihypertensive therapy on serum lipids / B.L. Kasiske [et al.]  Ann Intern Med. – 1995 122:133-141.
  14. Fazal M.A. Dyslipidaemia among renal transplant recipients: cyclosporine versus tacrolimus [Text]/ M.A. Fazal, M.K. Idrees, S.F. Akhtar  J Pak Med Assoc. 2014 64(5):496-499.
  15. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease [Text] / D. Fliser [et al.] Kidney international. – 1998 53(5):1343-1347.
  16. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation [Text] / G.F. Watts [et al.]  Int J Cardiol. – 2014 171(3):309-325.
  17. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk [Text] / S.I. Hallan [et al.]  J Am Soc Nephrol. – 2006 17:2275-2284.
  18. Iqbal A. Serum lipid levels in relation to serum thyroid stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study [Text] / A. Iqbal, R. Jorde, Y. Figenschau  J Intern Med. – 2006 260:53-57.
  19. Kelley D.E. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus [Text] / D.E. Kelley, J.A. Simoneau  J Clin Invest. – 1994 94:253-259.
  20. Kidney disease as a risk factor for development of cardiovascular disease P. a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research Clinical Cardiology, and Epidemiology and Prevention / M.J. Sarnak [et al.] Circulation. – 2003 108:2154-2169.

file

download